Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA : a Nationwide Cross-Section Study
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new terminology characterized by liver steatosis. Iron status is related to many metabolic diseases. However, the researches on the associations of serum iron status with MAFLD are limited. The objective of this study was to investigate the associations of serum iron status biomarkers with MAFLD and liver fibrosis. A total of 5892 adults were enrolled in the current cross-sectional study using the 2017-March 2020 National Health and Nutrition Examination Survey. Liver steatosis and liver fibrosis were defined by the median values of controlled attenuation parameter ≥ 274 dB/m and liver stiffness measurement ≥ 8 kPa, respectively. The multivariable logistic/linear regression and restricted cubic spline analysis were conducted. After adjusting for potential confounders, higher ferritin levels were associated with higher odds of MAFLD (OR 4.655; 95% CI 2.301, 9.418) and liver fibrosis (OR 7.013; 95% CI 3.910, 12.577). Lower iron levels were associated with a higher prevalence of MAFLD (OR 0.622; 95% CI 0.458, 0.844) and liver fibrosis (OR 0.722; 95% CI 0.536, 0.974). Lower transferrin saturation (TSAT) was associated with a higher prevalence of MAFLD (OR 0.981; 95% CI 0.970, 0.991) and liver fibrosis (OR 0.988; 95% CI 0.979, 0.998). Higher ferritin levels, lower iron levels, and TSAT were associated with a higher prevalence of MAFLD and liver fibrosis. This study extended the knowledge of modifying iron status to prevent MAFLD and liver fibrosis. More prospective and mechanism studies were warranted to confirm the conclusions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:202 |
|---|---|
| Enthalten in: |
Biological trace element research - 202(2024), 1 vom: 04. Jan., Seite 87-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Genfeng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 04.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12011-023-03666-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355830639 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355830639 | ||
| 003 | DE-627 | ||
| 005 | 20240108141553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12011-023-03666-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM355830639 | ||
| 035 | |a (NLM)37079265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Genfeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA |b a Nationwide Cross-Section Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new terminology characterized by liver steatosis. Iron status is related to many metabolic diseases. However, the researches on the associations of serum iron status with MAFLD are limited. The objective of this study was to investigate the associations of serum iron status biomarkers with MAFLD and liver fibrosis. A total of 5892 adults were enrolled in the current cross-sectional study using the 2017-March 2020 National Health and Nutrition Examination Survey. Liver steatosis and liver fibrosis were defined by the median values of controlled attenuation parameter ≥ 274 dB/m and liver stiffness measurement ≥ 8 kPa, respectively. The multivariable logistic/linear regression and restricted cubic spline analysis were conducted. After adjusting for potential confounders, higher ferritin levels were associated with higher odds of MAFLD (OR 4.655; 95% CI 2.301, 9.418) and liver fibrosis (OR 7.013; 95% CI 3.910, 12.577). Lower iron levels were associated with a higher prevalence of MAFLD (OR 0.622; 95% CI 0.458, 0.844) and liver fibrosis (OR 0.722; 95% CI 0.536, 0.974). Lower transferrin saturation (TSAT) was associated with a higher prevalence of MAFLD (OR 0.981; 95% CI 0.970, 0.991) and liver fibrosis (OR 0.988; 95% CI 0.979, 0.998). Higher ferritin levels, lower iron levels, and TSAT were associated with a higher prevalence of MAFLD and liver fibrosis. This study extended the knowledge of modifying iron status to prevent MAFLD and liver fibrosis. More prospective and mechanism studies were warranted to confirm the conclusions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Iron Status | |
| 650 | 4 | |a Liver Steatosis | |
| 650 | 4 | |a MAFLD | |
| 650 | 4 | |a Metabolic Dysfunction-associated Fatty Liver Disease | |
| 650 | 4 | |a NHANES | |
| 650 | 4 | |a Vibration-controlled Transient Elastography | |
| 650 | 7 | |a milameline |2 NLM | |
| 650 | 7 | |a R9X77R42FN |2 NLM | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Ferritins |2 NLM | |
| 650 | 7 | |a 9007-73-2 |2 NLM | |
| 700 | 1 | |a Liu, Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yaosheng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xingying |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Hualin |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yuqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Huixian |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Heng |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Jie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biological trace element research |d 1979 |g 202(2024), 1 vom: 04. Jan., Seite 87-98 |w (DE-627)NLM012611972 |x 1559-0720 |7 nnns |
| 773 | 1 | 8 | |g volume:202 |g year:2024 |g number:1 |g day:04 |g month:01 |g pages:87-98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12011-023-03666-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 202 |j 2024 |e 1 |b 04 |c 01 |h 87-98 | ||